These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. BAY58-2667 Activates Different Soluble Guanylyl Cyclase Species by Distinct Mechanisms that Indicate Its Principal Target in Cells is the Heme-Free Soluble Guanylyl Cyclase-Heat Shock Protein 90 Complex. Dai Y; Stuehr DJ Mol Pharmacol; 2023 May; 103(5):286-296. PubMed ID: 36868790 [TBL] [Abstract][Full Text] [Related]
5. Responsiveness of rat aorta and pulmonary artery to cGMP generators in the presence of thiol or heme oxidant. Tawa M; Yamashita Y; Masuoka T; Nakano K; Yoshida J; Nishio M; Ishibashi T J Pharmacol Sci; 2019 May; 140(1):43-47. PubMed ID: 31036520 [TBL] [Abstract][Full Text] [Related]
6. Hydrogen sulfide regulates the redox state of soluble guanylate cyclase in CSE Olivencia MA; Esposito E; Brancaleone V; Castaldo S; Cirino G; Pérez-Vizcaino F; Sorrentino R; d'Emmanuele di Villa Bianca R; Mitidieri E Pharmacol Res; 2023 Aug; 194():106834. PubMed ID: 37343646 [TBL] [Abstract][Full Text] [Related]
7. Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. Tsai EJ; Liu Y; Koitabashi N; Bedja D; Danner T; Jasmin JF; Lisanti MP; Friebe A; Takimoto E; Kass DA Circ Res; 2012 Jan; 110(2):295-303. PubMed ID: 22095726 [TBL] [Abstract][Full Text] [Related]
8. Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta. Korkmaz S; Loganathan S; Mikles B; Radovits T; Barnucz E; Hirschberg K; Li S; Hegedüs P; Páli S; Weymann A; Karck M; Szabó G J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):70-7. PubMed ID: 22914857 [TBL] [Abstract][Full Text] [Related]
9. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770. Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320 [TBL] [Abstract][Full Text] [Related]
10. Regulation of the expression of soluble guanylyl cyclase by reactive oxygen species. Gerassimou C; Kotanidou A; Zhou Z; Simoes DC; Roussos C; Papapetropoulos A Br J Pharmacol; 2007 Apr; 150(8):1084-91. PubMed ID: 17339839 [TBL] [Abstract][Full Text] [Related]
11. Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice. Wang WZ; Jones AW; Wang M; Durante W; Korthuis RJ Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H521-32. PubMed ID: 23771693 [TBL] [Abstract][Full Text] [Related]
13. Targeting heme-oxidized soluble guanylate cyclase to promote osteoblast function. Tesfamariam B Drug Discov Today; 2020 Feb; 25(2):422-429. PubMed ID: 31846712 [TBL] [Abstract][Full Text] [Related]
14. Loss of smooth muscle CYB5R3 amplifies angiotensin II-induced hypertension by increasing sGC heme oxidation. Durgin BG; Hahn SA; Schmidt HM; Miller MP; Hafeez N; Mathar I; Freitag D; Sandner P; Straub AC JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31487266 [TBL] [Abstract][Full Text] [Related]
15. Hydrogen sulfide dysfunction in metabolic syndrome-associated vascular complications involves cGMP regulation through soluble guanylyl cyclase persulfidation. Smimmo M; Casale V; Casillo GM; Mitidieri E; d'Emmanuele di Villa Bianca R; Bello I; Schettino A; Montanaro R; Brancaleone V; Indolfi C; Cirino G; Di Lorenzo A; Bucci M; Panza E; Vellecco V Biomed Pharmacother; 2024 May; 174():116466. PubMed ID: 38552439 [TBL] [Abstract][Full Text] [Related]
16. Effects of hydrogen peroxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries. Tawa M; Shimosato T; Iwasaki H; Imamura T; Okamura T Free Radic Res; 2015; 49(12):1479-87. PubMed ID: 26334090 [TBL] [Abstract][Full Text] [Related]
17. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Zhou Z; Pyriochou A; Kotanidou A; Dalkas G; van Eickels M; Spyroulias G; Roussos C; Papapetropoulos A Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1763-71. PubMed ID: 18757489 [TBL] [Abstract][Full Text] [Related]
18. Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model. Turgut NH; Temiz TK; Turgut B; Karadas B; Parlak M; Bagcivan I Can J Physiol Pharmacol; 2013 Oct; 91(10):797-803. PubMed ID: 24144050 [TBL] [Abstract][Full Text] [Related]
19. BAY 60-2770 activates two isoforms of nitric oxide sensitive guanylyl cyclase: Evidence for stable insertion of activator drugs. Sömmer A; Sandner P; Behrends S Biochem Pharmacol; 2018 Jan; 147():10-20. PubMed ID: 29155144 [TBL] [Abstract][Full Text] [Related]
20. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells. Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]